BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang W, Shen Y, Huang H, Pan S, Jiang J, Chen W, Zhang T, Zhang C, Ni C. A Rosetta Stone for Breast Cancer: Prognostic Value and Dynamic Regulation of Neutrophil in Tumor Microenvironment. Front Immunol 2020;11:1779. [PMID: 32849640 DOI: 10.3389/fimmu.2020.01779] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Identification of Lysosome-related Biomarkers for Predicting Prognosis and Immunotherapeutic Response in Breast Cancer.. [DOI: 10.21203/rs.3.rs-2405680/v2] [Reference Citation Analysis]
2 Charles A, Thomas RM. The Influence of the microbiome on the innate immune microenvironment of solid tumors. Neoplasia 2023;37:100878. [PMID: 36696837 DOI: 10.1016/j.neo.2023.100878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang J, Wang X, Duan M, Zhang Z, Jiang M, Li J, Liu X, Ren Y, Wang Y, Jia H. Identification of Lysosome-related Biomarkers for Predicting Prognosis and Immunotherapeutic Response in Breast Cancer.. [DOI: 10.21203/rs.3.rs-2405680/v1] [Reference Citation Analysis]
4 Xie T, Liu B, Liu D, Zhou Y, Yang Q, Wang D, Tang M, Liu W. Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma. Front Pharmacol 2022;13:1103986. [PMID: 36618928 DOI: 10.3389/fphar.2022.1103986] [Reference Citation Analysis]
5 Sifón MDR, Marcolini N, Barber MJ, Mclean I, Rizzo M, Rivero S, Costanzo MV, Nervo A, Crimi G, Perazzo F, Levy EM, Mandó P. Lack of Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Early Breast Cancer. Breast Care (Basel) 2022;17:546-53. [PMID: 36590145 DOI: 10.1159/000525287] [Reference Citation Analysis]
6 Zhu X, Wang T, Jia H, Wu F. Immunocyte‐Derived Nanodrugs for Cancer Therapy. Adv Funct Materials. [DOI: 10.1002/adfm.202207181] [Reference Citation Analysis]
7 Tommasi C, Pellegrino B, Diana A, Palafox Sancez M, Orditura M, Scartozzi M, Musolino A, Solinas C. The Innate Immune Microenvironment in Metastatic Breast Cancer. JCM 2022;11:5986. [DOI: 10.3390/jcm11205986] [Reference Citation Analysis]
8 He X, Wang J, Yu H, Lv W, Wang Y, Zhang Q, Liu Z, Wu Y. Clinical significance for diagnosis and prognosis of POP1 and its potential role in breast cancer: a comprehensive analysis based on multiple databases. Aging (Albany NY) 2022;14. [PMID: 36084948 DOI: 10.18632/aging.204255] [Reference Citation Analysis]
9 Zhao H, Xie R, Zhang C, Lu G, Kong H. Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors. Front Genet 2022;13:989460. [DOI: 10.3389/fgene.2022.989460] [Reference Citation Analysis]
10 Gianni C, Palleschi M, Schepisi G, Casadei C, Bleve S, Merloni F, Sirico M, Sarti S, Cecconetto L, Di Menna G, Schettini F, De Giorgi U. Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment. Front Oncol 2022;12:882896. [DOI: 10.3389/fonc.2022.882896] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu B, Shi T, Tian S, Luo X, Yang C, Wen J. Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia. Evid Based Complement Alternat Med 2022;2022:9192655. [PMID: 35795277 DOI: 10.1155/2022/9192655] [Reference Citation Analysis]
12 Zhao H, Lu G. Prognostic Implication and Immunological Role of PSMD2 in Lung Adenocarcinoma. Front Genet 2022;13:905581. [PMID: 35754829 DOI: 10.3389/fgene.2022.905581] [Reference Citation Analysis]
13 Yu S, Li W, Tang L, Fan X, Yao S, Zhang X, Bi Z, Cheng H. Depression in breast cancer patients: Immunopathogenesis and immunotherapy. Cancer Letters 2022;536:215648. [DOI: 10.1016/j.canlet.2022.215648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Qiao H, Lv R, Pang Y, Yao Z, Zhou X, Zhu W, Zhou W, Rasool M. Weighted Gene Coexpression Network Analysis Identifies TBC1D10C as a New Prognostic Biomarker for Breast Cancer. Analytical Cellular Pathology 2022;2022:1-20. [DOI: 10.1155/2022/5259187] [Reference Citation Analysis]
15 Locy H, Verhulst S, Cools W, Waelput W, Brock S, Cras L, Schiettecatte A, Jonckheere J, van Grunsven LA, Vanhoeij M, Thielemans K, Breckpot K. Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring. Front Immunol 2022;13:794175. [DOI: 10.3389/fimmu.2022.794175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
16 Segovia-mendoza M, Fernández-lópez BE, Lemini C, Carlos-reyes A, Prado-garcia H. Role of Membrane Estrogen Receptor (GPER1) on the Function of Immune Cells and Its Consequences on Breast Cancer Pathophysiology. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_48] [Reference Citation Analysis]
17 Bartlett DB, Hanson ED, Lee JT, Wagoner CW, Harrell EP, Sullivan SA, Bates LC, Alzer MS, Amatuli DJ, Deal AM, Jensen BC, MacDonald G, Deal MA, Muss HB, Nyrop KA, Battaglini CL. The Effects of 16 Weeks of Exercise Training on Neutrophil Functions in Breast Cancer Survivors. Front Immunol 2021;12:733101. [PMID: 34777343 DOI: 10.3389/fimmu.2021.733101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cilibrasi C, Papanastasopoulos P, Samuels M, Giamas G. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. Int J Mol Sci 2021;22:12015. [PMID: 34769447 DOI: 10.3390/ijms222112015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Qin Q, Fang DL, Zhou W, Meng Y, Wei J. Classification and immune invasion analysis of breast cancer based on m6A genes. Ann Transl Med 2021;9:1418. [PMID: 34733970 DOI: 10.21037/atm-21-3404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yi Y, Wu M, Zeng H, Hu W, Zhao C, Xiong M, Lv W, Deng P, Zhang Q, Wu Y. Tumor-Derived Exosomal Non-Coding RNAs: The Emerging Mechanisms and Potential Clinical Applications in Breast Cancer. Front Oncol 2021;11:738945. [PMID: 34707990 DOI: 10.3389/fonc.2021.738945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
21 Liu F, Li L, Lan M, Zou T, Kong Z, Cai T, Wu XY, Cai Y. Key Factor Regulating Inflammatory Microenvironment, Metastasis, and Resistance in Breast Cancer: Interleukin-1 Signaling. Mediators Inflamm 2021;2021:7785890. [PMID: 34602858 DOI: 10.1155/2021/7785890] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Schuler LA, Murdoch FE. Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers. Cancers (Basel) 2021;13:3725. [PMID: 34359625 DOI: 10.3390/cancers13153725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Grassadonia A, Graziano V, Iezzi L, Vici P, Barba M, Pizzuti L, Cicero G, Krasniqi E, Mazzotta M, Marinelli D, Amodio A, Natoli C, Tinari N. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. Cells 2021;10:1685. [PMID: 34359855 DOI: 10.3390/cells10071685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
24 De Re V, Caggiari L, Mascarin M, De Zorzi M, Elia C, Repetto O, Mussolin L, Pillon M, Muggeo P, Buffardi S, Bianchi M, Sala A, Vinti L, Farruggia P, Facchini E, Lopci E, d’Amore E, Burnelli R, with the A.I.E.O.P. Consortium. A Score for Predicting Freedom from Progression of Children and Adolescents with Hodgkin Lymphoma. Hemato 2021;2:264-280. [DOI: 10.3390/hemato2020016] [Reference Citation Analysis]
25 Huang H, Zhou J, Chen H, Li J, Zhang C, Jiang X, Ni C. The immunomodulatory effects of endocrine therapy in breast cancer. J Exp Clin Cancer Res 2021;40:19. [PMID: 33413549 DOI: 10.1186/s13046-020-01788-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]